<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03637140</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00455_A8</org_study_id>
    <nct_id>NCT03637140</nct_id>
  </id_info>
  <brief_title>Acute Exposure of Simulated Hypoxia on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise</brief_title>
  <official_title>Acute Exposure to Hypoxia in Precapillary Pulmonary Hypertension: Physiological and Clinical Effects at Rest and During Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the
      acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on
      pulmonary artery pressure and right heart function (echo) under exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low altitude baseline measurements will be performed in Zurich (460m asl) including
      Echocardiography, Right heart catheterization, six-minute walk test (6MWT), pulmonary
      function test, clinical assessment and blood gas Analysis. Randomly assigned to the order of
      testing, the participants will be tested under simulated altitude (FiO2: 15.1% with the &quot;AMC
      Altitrainer&quot;) and shamed altitude with the same device. Several times within the exposure,
      the pulmonary artery pressure and the right heart function will be assessed by echo under
      exercise.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Including a baseline assessment and assessments under simulated altitude and normoxia.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The allocated gas mixture will not be disclosed to the patient since he will breath through a facemask during both interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic Assessment under hypoxia during exercise</measure>
    <time_frame>1 day at altitude</time_frame>
    <description>Pulmonary artery pressure assessed under exercise by echo (TTE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic right heart functions under hypoxia during exercise</measure>
    <time_frame>1 day at altitude</time_frame>
    <description>Right heart function (fac, D-Shaping, Cardiac Output) assessed by echocardiography under exercise</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Order A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (&quot;Altitrainer, SMTEC&quot;), simulated altitude (FiO2: 15.1%), with a facemask.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Order B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (&quot;Altitrainer, SMTEC&quot;) with a facemask.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Simulated Altitude (FiO2: 15.1%)</intervention_name>
    <description>Inhalation of deoxygenated air through a altitude simulator (&quot;Altitrainer&quot;), for approx. 1 hour. given by a facemask.</description>
    <arm_group_label>Order A</arm_group_label>
    <arm_group_label>Order B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shamed Hypoxia (FiO2: 20.9)</intervention_name>
    <description>Inhalation of unmodified air through an altitude simulator (&quot;Altitrainer&quot;) for approximately 1 hour given by a facemask</description>
    <arm_group_label>Order A</arm_group_label>
    <arm_group_label>Order B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  PH diagnosed according to internation Guidelines: mean pulmonary artery pressure
             (mPAP) ≥ 25 mmHg along with a pulmonary artery wedge pressure (PAWP) ≤15 mmHg during
             right heart catheterization at the time of Initial diagnosis

          -  PH class 1 (PAH) or 4 (CTEPH)

          -  Stable condition, on the same medication for &gt; 4 weeks

          -  Patient live permanently at an altitude &lt; 1000m asl.

        Exclusion Criteria:

          -  Resting partial oxygen pressure (PaO2) ≤7.3 kilopascal (kPA) corresponding to the
             requirement of long-term oxygen therapy &gt; 16hour daily (nocturnal oxygen therapy alone
             is allowed)

          -  Severe daytime hypercapnia (pCO2 &gt; 6.5 kPa)

          -  Susceptibility to high altitude related diseases (AMS, high-altitude pulmonary edema
             (HAPE), etc.) based on previous experienced discomfort at altitudes.

          -  Exposure to an altitude &gt;1500m for ≥3 nights during the last 4 weeks before the study
             participation

          -  Residence &gt; 1000m above sea level

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, neurological or orthopedic problems with Walking disability

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory Clinic, University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Simulated altitude</keyword>
  <keyword>Pulmonary artery pressure</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Right heart function</keyword>
  <keyword>exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

